scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.YGYNO.2016.11.043 |
P698 | PubMed publication ID | 27931751 |
P50 | author | Franco Muggia | Q30512486 |
Leslie Boyd | Q38801338 | ||
John P. Curtin | Q38801361 | ||
Judith D. Goldberg | Q48328661 | ||
Bhavana Pothuri | Q85856253 | ||
Stephanie V Blank | Q91909560 | ||
Amy Tiersten | Q101403740 | ||
Fernanda Musa | Q117265819 | ||
P2093 | author name string | Xiaochun Li | |
Huichung T Ling | |||
James L Speyer | |||
P2860 | cites work | Cancer statistics, 2013 | Q27860762 |
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study | Q28258045 | ||
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha | Q28259513 | ||
A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma | Q33330638 | ||
Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer | Q33331282 | ||
Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. | Q33552740 | ||
Targeting hypoxia cell signaling for cancer therapy | Q36784388 | ||
Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells | Q40483692 | ||
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors | Q40550209 | ||
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications | Q40585883 | ||
Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model | Q42573981 | ||
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. | Q44276671 | ||
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia | Q46114146 | ||
Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer | Q46135004 | ||
Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer | Q46892024 | ||
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma | Q48264845 | ||
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study | Q84676387 | ||
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial | Q87460208 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | irinotecan | Q412197 |
bevacizumab | Q413299 | ||
ovarian cancer | Q172341 | ||
P304 | page(s) | 279-284 | |
P577 | publication date | 2016-12-05 | |
P1433 | published in | Gynecologic Oncology | Q5625182 |
P1476 | title | Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer | |
P478 | volume | 144 |
Q100385888 | A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer |
Q38687169 | Identification of Pharmacologically Tractable Protein Complexes in Cancer Using the R-Based Network Clustering and Visualization Program MCODER. |
Q52362144 | Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. |
Q49788115 | Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis. |
Q92594112 | Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities |
Q99583257 | Secondary and tertiary ovarian cancer recurrence: what is the best management? |
Q96022689 | Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy |
Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
Search more.